Pfizer Inc. (NYSE:PFE) is one of the more popular stocks investors are adding into their watchlist. Now trading with a market value of 243.28B, the company has a mix of catalysts and obstacles that spring from the nature of its operations. Everyone seems to have their own opinion of this stock. But what do the numbers really say? We think it’s a great time to take a fresh look.Pfizer Inc. (NYSE:PFE) Fundamentals That Matter
It’s generally a good idea to start with the most fundamental piece of the picture: the balance sheet. The balance sheet health of any company plays a key role in its ability to meet its obligations and maintain the faith of its investment base. The trend over time is important to note. In this case, the company’s debt has been growing.Pfizer Inc. (NYSE:PFE) Revenue Growth Potential
As far as key trends that demonstrate something of the future investment potential of this stock, we need to take a closer look at the top line, first and foremost. Last quarter, the company saw 13.47 billion in total revenues. That represents a quarterly year/year change in revenues of 0.04 in sequential terms, the PFE saw sales decline by 0.04.
But what about the bottom line? After all, that’s what really matters in the end. Pfizer Inc. (PFE) is intriguing when broken down to its core data. The cost of selling goods last quarter was 2.92 billion, yielding a gross basic income of 10.55 billion. For shareholders, given the total diluted outstanding shares of 5.95 billion, this means overall earnings per share of 0.65. Note, this compares with a consensus analyst forecast of 0.67 in earnings per share for its next fiscal quarterly report.Is Pfizer Inc. (NYSE:PFE) Valuation Attractive
Looking ahead at valuations, according to the consensus, the next fiscal year is forecast to bring about 3.06 in total earnings per share. If we consider a median price to earnings ratio on the stock, that corresponds with a stock price of 13.10. However, one should always remember: the trends are more important than the forecasts. This continues to be an interesting story, and we look forward to updating it again soon on Pfizer Inc..